U.S. Capital Wealth Advisors, LLC Gilead Sciences, Inc. Transaction History
U.S. Capital Wealth Advisors, LLC
- $2.46 Billion
- Q2 2024
A detailed history of U.S. Capital Wealth Advisors, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, U.S. Capital Wealth Advisors, LLC holds 75,771 shares of GILD stock, worth $6.35 Million. This represents 0.21% of its overall portfolio holdings.
Number of Shares
75,771
Previous 79,774
5.02%
Holding current value
$6.35 Million
Previous $5.84 Million
11.04%
% of portfolio
0.21%
Previous 0.24%
Shares
12 transactions
Others Institutions Holding GILD
# of Institutions
1,879Shares Held
1.02BCall Options Held
12MPut Options Held
8.96M-
Black Rock Inc. New York, NY121MShares$10.1 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$9.66 Billion0.15% of portfolio
-
Capital World Investors Los Angeles, CA76.2MShares$6.39 Billion0.88% of portfolio
-
Capital Research Global Investors Los Angeles, CA60.4MShares$5.07 Billion0.94% of portfolio
-
State Street Corp Boston, MA59.3MShares$4.97 Billion0.18% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $105B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...